Aneuploidy drives lethal progression in prostate cancer
Abstract
Aneuploidy is usually quantified by measuring intracellular DNA content or chromosome structure and number. We show that the number of altered chromosome arms can be estimated from transcriptome profiling, which allows for assessing aneuploidy within repositories of archival, formalin-fixed, paraffin-embedded tumors. While aneuploidy impedes proliferation in primary cells, we show that it is a feature of aggressiveness in primary prostate cancers that are more likely to become lethal. Our data suggest that losses or gains of entire chromosome arms confers aggressiveness beyond affecting copy numbers of tumor suppressors or oncogenes on those arms. Beyond helping understand the etiology of aggressive prostate cancer, we propose that extent of aneuploidy could also be employed clinically to inform risk stratification and treatment.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 13, 2019
- Source ID
- 10.1073/pnas.1902645116
Entities
People
- Angelika Amon
- Charles A Whittaker
- Konrad H Stopsack
- Lorelei A. Mucci
- Massimo Loda
- Philip W. Kantoff
- Travis A. Gerke
Organizations
- Dana–Farber Cancer Institute
- H. Lee Moffitt Cancer Center & Research Institute
- Harvard Medical School
- Harvard University
- Howard Hughes Medical Institute
- Massachusetts Institute of Technology
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute
- National Institute of General Medical Sciences
- Prostate Cancer Foundation
- United States Department of Defense